When emerging small and midsized biopharmaceutical firms are ready to take their therapies to the clinical study phase, the stakes are high. Will the therapy be safe and effective in a clinical setting, or will researchers have to go back to the lab for further development? Many of these emerging firms have spent years focusing exclusively on developing their therapies, so the clinical trial phase can seem daunting.
That’s where companies like Veristat come in, offering clinical development services and expertise for this critical next step. Veristat is a full-service CRO that helps pharmaceutical and biotechnology development firms complete clinical trials and prepare regulatory submissions to the US Food and Drug Administration (FDA) and other regulatory agencies for approval. Veristat applies its 25 years of clinical and regulatory expertise across multiple medical disciplines, including oncology, infectious diseases, neurology, cardiology and respiratory, with considerable expertise in rare diseases.
To strengthen best practices and offer its customers the best solutions possible, Veristat needed an EDC solution that it knew could support a wide variety of studies and study parameters. The IBM® Clinical Development solution armed Veristat with a powerful clinical research platform that provides fully integrated advanced modules, such as medical coding and randomization, that help the organization continue to simplify clinical study processes and increase overall trial efficiency.